Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib Plus Letrozole in Recurrent Low-Grade Serous Carcinoma
NCT03673124Phase 2Active, not recruiting
- Sponsor
- GOG Foundation
- Start
- May 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib in serous carcinoma, sponsored by GOG Foundation. Started May 2019; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
serous carcinoma
Beyond the preview
Go deeper on NCT03673124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673124.